| Name | Title | Contact Details |
|---|
California-based Finesse Solutions brings Silicon Valley technology to bioprocessing. Better performance, integrated intelligence, and plug-and-play bioprocess flexibility are provided by Finesse SmartParts™. Our TruFluor® single-use sensors are unparalleled in the industry. Our G3 Universal™ controllers enable sophisticated cell culture or fermentation recipes to run on any size or brand of vessel. Our TruBio® software provides an easy-to-use interface for upstream bioprocessing that can harmonize old and new equipment, aggregate in-line and off-line data, and electronically facilitate global technology transfer. Finesse enables you to supercharge your R&D laboratory or scale-up to a cGMP SmartFactory with equal ease: we offer complete services, including commissioning and validation.
RightCHOICE Benefit Administrators is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VHA Inc. is a national network of not-for-profit health care organizations working together to improve performance and efficiency in clinical, financial and operational management. Since 1977, when VHA established the first hospital membership organization, the company has applied its knowledge in analytics, contracting, consulting and network development to help members and customers achieve their strategic objectives. In 2012, VHA delivered $1.9 billion in savings and additional value to members. Serving 5,100 health system members and affiliates, VHA represents more than a quarter of the nation's hospitals. VHA also serves more than 118,000 non-acute health care customers enterprise-wide. VHA is based in Irving, Texas, and has 12 regional offices across the U.S. VHA, together with UHC, owns Novation, a supply chain company, and aptitude™ , the health care industry's first online direct contracting market. VHA also owns Provista, a supply chain company serving the non-acute market as well as hospitality, education and corporate markets.
Adelphi International Research is a Doylestown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.